Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) announced on October 21, 2025 that it purchased an additional $200,000 of Ethereum (ETH), bringing its total ETH holdings to $2 million.

The acquisition was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify and strengthen its long‑term asset base through targeted digital asset investments.

Cosmos Health (NASDAQ:COSM) announced on October 16, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. Nasdaq confirmed the company’s closing bid price was at or above $1.00 for 18 consecutive business days from September 22, 2025 to October 15, 2025. As a result, Nasdaq has closed the matter and the Company is now in compliance with the listing rule. The company said this compliance was achieved organically and attributed to execution of strategic initiatives and strengthening fundamentals, and reiterated focus on shareholder value and its digital asset strategy.

Cosmos Health (NASDAQ:COSM) announced on October 13, 2025 that it purchased an additional $300,000 of Ethereum (ETH), bringing its total ETH holdings to $1.8 million. The purchase was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify holdings via strategic digital asset investments. Management reiterated commitment to continue the acquisition program under the financing facility.

Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.

Cosmos Health (NASDAQ:COSM) announced that subsidiary SkyPharm S.A. signed an exclusive distribution agreement dated September 28, 2025 with Diyar United to market and sell Sky Premium Life® nutraceuticals in Kuwait. Diyar United will manage registration, promotion, logistics and distribution for formulations including collagen, hyaluronic acid, vitamins B/C/D3+K2, magnesium, zinc, turmeric, maca, rhodiola, multivitamins and hair/skin/nail blends. Cosmos secured an initial purchase order of over 65,000 units, with further orders expected as the sales pipeline develops. The PR cites Kuwait’s supplements market at $1.16B in 2024, projected to $1.68B by 2030 (CAGR ~6.3%).

Cosmos Health (NASDAQ:COSM) CEO Greg Siokas outlined the company's transformation into a global healthcare powerhouse, highlighting several major developments. The company secured a $300 million digital financing facility, with 72.5% allocated to building a digital treasury reserve in cryptocurrencies and the remainder for working capital and growth initiatives.

Key achievements include: expansion of U.S. manufacturing operations through NOOR Collagen partnership, significant growth of Sky Premium Life brand across multiple international markets, and record performance from CosmoFarm wholesale division with $43 million revenue in first 10 months of 2024. The company's Cana Laboratories secured major contracts, including a 10-year agreement for 8 million packs with Provident Pharmaceuticals.

The company advanced its R&D pipeline, particularly with obesity treatment CCX0722, and expanded its portfolio through acquisitions and partnerships in pharmaceuticals and diagnostics.

Cosmos Health (NASDAQ:COSM) has announced that its subsidiary Cana Laboratories has secured a contract manufacturing agreement with Medical Pharmaquality S.A. for the production of MYCOFAGYL® pessaries. The agreement entails manufacturing 3 million pessaries annually, packaged in 10-unit sets.

MYCOFAGYL® combines Metronidazole (500mg) and Nystatin (100,000 IU) to treat vaginal infections, including bacterial vaginosis and candidiasis. This expansion into gynecological products represents a strategic diversification of Cana's manufacturing portfolio and strengthens its position in the European pharmaceutical market.

Cosmos Health (NASDAQ:COSM) has launched its U.S. operations by introducing its Sky Premium Life food supplements brand, marking its entry into the $164B U.S. nutraceuticals market. The company's first product, NOOR Collagen, is manufactured in FDA-registered, GMP-certified U.S. facilities.

The company projects 75% gross margins and expects NOOR Collagen alone to generate over $12M in annualized revenue. The U.S. nutraceuticals market is forecasted to grow at a 6.2% CAGR through 2030, driven by increasing health awareness and demand for natural wellness solutions.

This strategic expansion includes local manufacturing to mitigate tariff exposure and logistical risks, with plans for additional product launches to meet U.S. consumer demand.

Cosmos Health (NASDAQ:COSM) has signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplements in Oman. The deal includes an initial purchase order of 42,000 units and marks COSM's strategic entry into the GCC nutraceuticals market, valued at $6.91 billion in 2024.

Scientific Pharmacy, owned by Gulf Pharmaceutical Industries (Julphar), will manage regulatory compliance, product registration, distribution, marketing, and retail sales through its established network. The GCC nutraceuticals market is projected to reach $15.5 billion by 2033, growing at a CAGR of 8.7%, driven by increasing health awareness and higher disposable incomes.